In Phase 2, what is determined to evaluate safety margin?

In Phase 2, what is determined to evaluate safety margin?

• A. The marketing strategy.
• B. The manufacturing cost.
• C. The therapeutic index.
• D. The device compatibility.

Answer: (C)

The safety margin in drug testing is captured by the therapeutic index, a ratio that compares the dose that produces toxicity to the dose that provides the desired therapeutic effect (often TD50/ED50 or LD50/ED50). In Phase 2, researchers look at how a drug’s efficacy at various doses stacks up against the emergence of adverse effects, helping estimate this ratio in humans. A large therapeutic index means a wide safety margin—the drug can be dosed effectively without approaching toxic levels. A small therapeutic index means the opposite, where small increases in dose can lead to toxicity, making safety more delicate. Phase 2 uses these data to pick a dosing range that achieves good efficacy while staying well below toxic doses. Other factors like marketing strategy, manufacturing cost, or device compatibility aren’t about the drug’s safety margin.

The safety margin in drug testing is captured by the therapeutic index, a ratio that compares the dose that produces toxicity to the dose that provides the desired therapeutic effect (often TD50/ED50 or LD50/ED50). In Phase 2, researchers look at how a drug’s efficacy at various doses stacks up against the emergence of adverse effects, helping estimate this ratio in humans. A large therapeutic index means a wide safety margin—the drug can be dosed effectively without approaching toxic levels. A small therapeutic index means the opposite, where small increases in dose can lead to toxicity, making safety more delicate. Phase 2 uses these data to pick a dosing range that achieves good efficacy while staying well below toxic doses. Other factors like marketing strategy, manufacturing cost, or device compatibility aren’t about the drug’s safety margin.